{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T22:40:52Z","timestamp":1794523252037,"version":"4.9.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Engineered live bacteria could provide a new modality for treating lung infections, a major cause of mortality worldwide. In the present study, we engineered a genome-reduced human lung bacterium,\n                    <jats:italic>Mycoplasma pneumoniae<\/jats:italic>\n                    , to treat ventilator-associated pneumonia, a disease with high hospital mortality when associated with\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    biofilms. After validating the biosafety of an attenuated\n                    <jats:italic>M. pneumoniae<\/jats:italic>\n                    chassis in mice, we introduced four transgenes into the chromosome by transposition to implement bactericidal and biofilm degradation activities. We show that this engineered strain has high efficacy against an acute\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    lung infection in a mouse model. In addition, we demonstrated that the engineered strain could dissolve biofilms formed in endotracheal tubes of patients with ventilator-associated pneumonia and be combined with antibiotics targeting the peptidoglycan layer to increase efficacy against Gram-positive and Gram-negative bacteria. We expect our\n                    <jats:italic>M. pneumoniae<\/jats:italic>\n                    -engineered strain to be able to treat biofilm-associated infections in the respiratory tract.\n                  <\/jats:p>","DOI":"10.1038\/s41587-022-01584-9","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T12:04:49Z","timestamp":1674129889000},"page":"1089-1098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms"],"prefix":"10.1038","volume":"41","author":[{"given":"Rocco","family":"Mazzolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Rodr\u00edguez-Arce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7528-9636","authenticated-orcid":false,"given":"Laia","family":"Fern\u00e1ndez-Barat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-3702","authenticated-orcid":false,"given":"Carlos","family":"Pi\u00f1ero-Lambea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2497-7188","authenticated-orcid":false,"given":"Victoria","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-2713","authenticated-orcid":false,"given":"Agust\u00edn","family":"Rebollada-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Motos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-2167","authenticated-orcid":false,"given":"Antoni","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-0186","authenticated-orcid":false,"given":"Maria Jes\u00fas","family":"Grill\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-1392","authenticated-orcid":false,"given":"Luis","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-4353","authenticated-orcid":false,"given":"Maria","family":"Lluch-Senar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"1584_CR1","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.1039\/D0BM00974A","volume":"8","author":"S Wang","year":"2020","unstructured":"Wang, S., Gao, Y., Jin, Q. & Ji, J. Emerging antibacterial nanomedicine for enhanced antibiotic therapy. Biomater. Sci. 8, 6825\u20136839 (2020).","journal-title":"Biomater. Sci."},{"key":"1584_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2174\/1574886314666190612130921","volume":"14","author":"AMN Helaly","year":"2019","unstructured":"Helaly, A. M. N., El-Attar, Y. A., Khalil, M., Ahmed Ghorab, D. S. E.-D. & El- Mansoury, A. M. Antibiotic abuse induced histopathological and neurobehavioral disorders in mice. Curr. Drug Saf. 14, 199\u2013208 (2019).","journal-title":"Curr. Drug Saf."},{"key":"1584_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ijantimicag.2009.12.011","volume":"35","author":"N H\u00f8iby","year":"2010","unstructured":"H\u00f8iby, N., Bjarnsholt, T., Givskov, M., Molin, S. & Ciofu, O. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 35, 322\u2013332 (2010).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"1584_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/039139880602900408","volume":"29","author":"U Obst","year":"2006","unstructured":"Obst, U., Schwartz, T. & Volkmann, H. Antibiotic resistant pathogenic bacteria and their resistance genes in bacterial biofilms. Int. J. Artif. Organs 29, 387\u2013394 (2006).","journal-title":"Int. J. Artif. Organs"},{"key":"1584_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.addr.2005.04.007","volume":"57","author":"AW Smith","year":"2005","unstructured":"Smith, A. W. Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems? Adv. Drug Deliv. Rev. 57, 1539\u20131550 (2005).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1584_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1078\/1438-4221-00196","volume":"292","author":"PS Stewart","year":"2002","unstructured":"Stewart, P. S. Mechanisms of antibiotic resistance in bacterial biofilms. Int. J. Med. Microbiol. 292, 107\u2013113 (2002).","journal-title":"Int. J. Med. Microbiol."},{"key":"1584_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/sj.clpt.6100247","volume":"82","author":"JL del Pozo","year":"2007","unstructured":"del Pozo, J. L. & Patel, R. The challenge of treating biofilm-associated bacterial infections. Clin. Pharmacol. Ther. 82, 204\u2013209 (2007).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1584_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fcimb.2020.00213","volume":"10","author":"AL Welp","year":"2020","unstructured":"Welp, A. L. & Bomberger, J. M. Bacterial community interactions during chronic respiratory disease. Front. Cell Infect. Microbiol. 10, 213 (2020).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1584_CR9","doi-asserted-by":"publisher","first-page":"e00873-17","DOI":"10.1128\/mBio.00873-17","volume":"8","author":"G Orazi","year":"2017","unstructured":"Orazi, G. & O\u2019Toole, G. A. Pseudomonas aeruginosa alters Staphylococcus aureus sensitivity to vancomycin in a biofilm model of cystic fibrosis infection. mBio 8, e00873-17 (2017).","journal-title":"mBio"},{"key":"1584_CR10","doi-asserted-by":"publisher","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"A Torres","year":"2017","unstructured":"Torres, A. et al. International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT). Eur. Respir. J. 50, 1700582 (2017).","journal-title":"Eur. Respir. J."},{"key":"1584_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/MCC.0000000000000536","volume":"24","author":"M Ferrer","year":"2018","unstructured":"Ferrer, M. & Torres, A. Epidemiology of ICU-acquired pneumonia. Curr. Opin. Crit. Care 24, 325\u2013331 (2018).","journal-title":"Curr. Opin. Crit. Care"},{"key":"1584_CR12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1574-6976.2011.00322.x","volume":"36","author":"EE Mann","year":"2012","unstructured":"Mann, E. E. & Wozniak, D. J. Pseudomonas biofilm matrix composition and niche biology. FEMS Microbiol. Rev. 36, 893\u2013916 (2012).","journal-title":"FEMS Microbiol. Rev."},{"key":"1584_CR13","doi-asserted-by":"publisher","unstructured":"Luo, Y., Yang, Q., Zhang, D. & Yan, W. Mechanisms and control strategies of antibiotic resistance in pathological biofilms. J. Microbiol. Biotechnol. https:\/\/doi.org\/10.4014\/jmb.2010.10021 (2020).","DOI":"10.4014\/jmb.2010.10021"},{"key":"1584_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00430-020-00691-1","volume":"209","author":"M Alhede","year":"2020","unstructured":"Alhede, M. et al. Bacterial aggregate size determines phagocytosis efficiency of polymorphonuclear leukocytes. Med. Microbiol. Immunol. 209, 669\u2013680 (2020).","journal-title":"Med. Microbiol. Immunol."},{"key":"1584_CR15","doi-asserted-by":"publisher","first-page":"e0241899","DOI":"10.1371\/journal.pone.0241899","volume":"16","author":"B Bortone","year":"2021","unstructured":"Bortone, B. et al. High global consumption of potentially inappropriate fixed dose combination antibiotics: analysis of data from 75 countries. PLoS ONE 16, e0241899 (2021).","journal-title":"PLoS ONE"},{"key":"1584_CR16","doi-asserted-by":"publisher","first-page":"102995","DOI":"10.1016\/j.ebiom.2020.102995","volume":"60","author":"L Fern\u00e1ndez-Barat","year":"2020","unstructured":"Fern\u00e1ndez-Barat, L., L\u00f3pez-Aladid, R. & Torres, A. Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome. eBioMedicine 60, 102995 (2020).","journal-title":"eBioMedicine"},{"key":"1584_CR17","doi-asserted-by":"publisher","unstructured":"On behalf of the coVAPid Study Group et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intens. Care Med. https:\/\/doi.org\/10.1007\/s00134-020-06323-9 (2021).","DOI":"10.1007\/s00134-020-06323-9"},{"key":"1584_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1164\/rccm.202106-1354OC","volume":"204","author":"CO Pickens","year":"2021","unstructured":"Pickens, C. O. et al. Bacterial superinfection pneumonia in patients mechanically ventilated for COVID-19 pneumonia. Am. J. Respir. Crit. Care Med. 204, 921\u2013932 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1584_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03588-4","volume":"25","author":"S Nseir","year":"2021","unstructured":"Nseir, S. et al. Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort. Crit. Care 25, 177 (2021).","journal-title":"Crit. Care"},{"key":"1584_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0926-5","volume":"19","author":"ST Micek","year":"2015","unstructured":"Micek, S. T. et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit. Care 19, 219 (2015).","journal-title":"Crit. Care"},{"key":"1584_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jinf.2016.11.008","volume":"74","author":"L Fern\u00e1ndez-Barat","year":"2017","unstructured":"Fern\u00e1ndez-Barat, L. et al. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance. J. Infect. 74, 142\u2013152 (2017).","journal-title":"J. Infect."},{"key":"1584_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fmed.2019.00099","volume":"6","author":"MS Niederman","year":"2019","unstructured":"Niederman, M. S. Adjunctive nebulized antibiotics: what is their place in ICU infections? Front. Med. 6, 99 (2019).","journal-title":"Front. Med."},{"key":"1584_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.mib.2013.06.002","volume":"16","author":"LG Berm\u00fadez-Humar\u00e1n","year":"2013","unstructured":"Berm\u00fadez-Humar\u00e1n, L. G. et al. Engineering lactococci and lactobacilli for human health. Curr. Opin. Microbiol. 16, 278\u2013283 (2013).","journal-title":"Curr. Opin. Microbiol."},{"key":"1584_CR24","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1053\/j.gastro.2006.03.031","volume":"130","author":"MJ Kuehn","year":"2006","unstructured":"Kuehn, M. J. Genetically engineered probiotic competition. Gastroenterology 130, 1915\u20131916 (2006).","journal-title":"Gastroenterology"},{"key":"1584_CR25","doi-asserted-by":"publisher","first-page":"e0176286","DOI":"10.1371\/journal.pone.0176286","volume":"12","author":"KE Durrer","year":"2017","unstructured":"Durrer, K. E., Allen, M. S. & Hunt von Herbing, I. Genetically engineered probiotic for the treatment of phenylketonuria (PKU): assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU. PLoS ONE 12, e0176286 (2017).","journal-title":"PLoS ONE"},{"key":"1584_CR26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1021\/sb4000417","volume":"2","author":"S Gupta","year":"2013","unstructured":"Gupta, S., Bram, E. E. & Weiss, R. Genetically programmable pathogen sense and destroy. ACS Synth. Biol. 2, 715\u2013723 (2013).","journal-title":"ACS Synth. Biol."},{"key":"1584_CR27","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1007\/s00253-019-09911-y","volume":"103","author":"ML Palma","year":"2019","unstructured":"Palma, M. L., Garcia-Bates, T. M., Martins, F. S. & Douradinha, B. Correction to: genetically engineered probiotic Saccharomyces cerevisiae strains mature human dendritic cells and stimulate gag-specific memory CD8+ T cells ex vivo. Appl. Microbiol. Biotechnol. 103, 5461 (2019).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"1584_CR28","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nbt840","volume":"21","author":"L Steidler","year":"2003","unstructured":"Steidler, L. et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21, 785\u2013789 (2003).","journal-title":"Nat. Biotechnol."},{"key":"1584_CR29","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.4161\/hv.28549","volume":"10","author":"R Mart\u00edn","year":"2014","unstructured":"Mart\u00edn, R. et al. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. Hum. Vaccines Immunother. 10, 1611\u20131621 (2014).","journal-title":"Hum. Vaccines Immunother."},{"key":"1584_CR30","doi-asserted-by":"publisher","first-page":"25441","DOI":"10.18632\/oncotarget.25192","volume":"9","author":"J Lalsiamthara","year":"2018","unstructured":"Lalsiamthara, J., Kim, J. H. & Lee, J. H. Engineering of a rough auxotrophic mutant Salmonella typhimurium for effective delivery. Oncotarget 9, 25441\u201325457 (2018).","journal-title":"Oncotarget"},{"key":"1584_CR31","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.289.5483.1352","volume":"289","author":"L Steidler","year":"2000","unstructured":"Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352\u20131355 (2000).","journal-title":"Science"},{"key":"1584_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0141-0229(00)00297-0","volume":"27","author":"L Schotte","year":"2000","unstructured":"Schotte, L., Steidler, L., Vandekerckhove, J. & Remaut, E. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb. Technol. 27, 761\u2013765 (2000).","journal-title":"Enzyme Microb. Technol."},{"key":"1584_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/mi.2009.116","volume":"3","author":"K Vandenbroucke","year":"2010","unstructured":"Vandenbroucke, K. et al. Orally administered L. lactis secreting an anti-TNF nanobody demonstrates efficacy in chronic colitis. Mucosal Immunol. 3, 49\u201356 (2010).","journal-title":"Mucosal Immunol."},{"key":"1584_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1053\/j.gastro.2004.05.020","volume":"127","author":"K Vandenbroucke","year":"2004","unstructured":"Vandenbroucke, K. et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 127, 502\u2013513 (2004).","journal-title":"Gastroenterology"},{"key":"1584_CR35","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1128\/AAC.00493-06","volume":"50","author":"X Liu","year":"2006","unstructured":"Liu, X. et al. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 50, 3250\u20133259 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1584_CR36","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1128\/AEM.00104-08","volume":"74","author":"X Liu","year":"2008","unstructured":"Liu, X., Lagenaur, L. A., Lee, P. P. & Xu, Q. Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Appl. Environ. Microbiol. 74, 4626\u20134635 (2008).","journal-title":"Appl. Environ. Microbiol."},{"key":"1584_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15508-1","volume":"11","author":"MR Charbonneau","year":"2020","unstructured":"Charbonneau, M. R., Isabella, V. M., Li, N. & Kurtz, C. B. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat. Commun. 11, 1738 (2020).","journal-title":"Nat. Commun."},{"key":"1584_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/138920110790725401","volume":"11","author":"E Kutter","year":"2010","unstructured":"Kutter, E. et al. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11, 69\u201386 (2010).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"1584_CR39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrmicro.2017.61","volume":"15","author":"J De Smet","year":"2017","unstructured":"De Smet, J., Hendrix, H., Blasdel, B. G., Danis-Wlodarczyk, K. & Lavigne, R. Pseudomonas predators: understanding and exploiting phage\u2013host interactions. Nat. Rev. Microbiol. 15, 517\u2013530 (2017).","journal-title":"Nat. Rev. Microbiol."},{"key":"1584_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14665","volume":"8","author":"M Trussart","year":"2017","unstructured":"Trussart, M. et al. Defined chromosome structure in the genome-reduced bacterium Mycoplasma pneumoniae. Nat. Commun. 8, 14665 (2017).","journal-title":"Nat. Commun."},{"key":"1584_CR41","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/msb.2013.6","volume":"9","author":"JAH Wodke","year":"2013","unstructured":"Wodke, J. A. H. et al. Dissecting the energy metabolism in Mycoplasma pneumoniae through genome-scale metabolic modeling. Mol. Syst. Biol. 9, 653 (2013).","journal-title":"Mol. Syst. Biol."},{"key":"1584_CR42","doi-asserted-by":"publisher","first-page":"e1501363","DOI":"10.1126\/sciadv.1501363","volume":"2","author":"V Llor\u00e9ns-Rico","year":"2016","unstructured":"Llor\u00e9ns-Rico, V. et al. Bacterial antisense RNAs are mainly the product of transcriptional noise. Sci. Adv. 2, e1501363 (2016).","journal-title":"Sci. Adv."},{"key":"1584_CR43","doi-asserted-by":"publisher","first-page":"780","DOI":"10.15252\/msb.20145558","volume":"11","author":"M Lluch-Senar","year":"2015","unstructured":"Lluch-Senar, M. et al. Defining a minimal cell: essentiality of small ORFs and ncRNAs in a genome-reduced bacterium. Mol. Syst. Biol. 11, 780 (2015).","journal-title":"Mol. Syst. Biol."},{"key":"1584_CR44","doi-asserted-by":"publisher","first-page":"e0137354","DOI":"10.1371\/journal.pone.0137354","volume":"10","author":"M Lluch-Senar","year":"2015","unstructured":"Lluch-Senar, M. et al. Comparative \u2018-omics\u2019 in Mycoplasma pneumoniae clinical isolates reveals key virulence factors. PLoS ONE 10, e0137354 (2015).","journal-title":"PLoS ONE"},{"key":"1584_CR45","doi-asserted-by":"publisher","first-page":"e9530","DOI":"10.15252\/msb.20209530","volume":"16","author":"R Burgos","year":"2020","unstructured":"Burgos, R., Weber, M., Martinez, S., Lluch\u2010Senar, M. & Serrano, L. Protein quality control and regulated proteolysis in the genome\u2010reduced organism Mycoplasma pneumoniae. Mol. Syst. Biol. 16, e9530 (2020).","journal-title":"Mol. Syst. Biol."},{"key":"1584_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cels.2019.07.001","volume":"9","author":"E Yus","year":"2019","unstructured":"Yus, E. et al. Determination of the gene regulatory network of a genome-reduced bacterium highlights alternative regulation independent of transcription factors. Cell Syst. 9, 143\u2013158.e13 (2019).","journal-title":"Cell Syst."},{"key":"1584_CR47","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/femsre\/fux033","volume":"41","author":"C Bl\u00f6tz","year":"2017","unstructured":"Bl\u00f6tz, C. & St\u00fclke, J. Glycerol metabolism and its implication in virulence in Mycoplasma. FEMS Microbiol. Rev. 41, 640\u2013652 (2017).","journal-title":"FEMS Microbiol. Rev."},{"key":"1584_CR48","doi-asserted-by":"publisher","first-page":"e02186-14","DOI":"10.1128\/mBio.02186-14","volume":"5","author":"S Bose","year":"2014","unstructured":"Bose, S. et al. ADP-ribosylation of NLRP3 by Mycoplasma pneumoniae CARDS toxin regulates inflammasome activity. mBio 5, e02186-14 (2014).","journal-title":"mBio"},{"key":"1584_CR49","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/j.1462-5822.2010.01513.x","volume":"12","author":"SR Somarajan","year":"2010","unstructured":"Somarajan, S. R., Kannan, T. R. & Baseman, J. B. Mycoplasma pneumoniae Mpn133 is a cytotoxic nuclease with a glutamic acid-, lysine- and serine-rich region essential for binding and internalization but not enzymatic activity. Cell. Microbiol. 12, 1821\u20131831 (2010).","journal-title":"Cell. Microbiol."},{"key":"1584_CR50","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1021\/acssynbio.0c00263","volume":"9","author":"L Garcia-Morales","year":"2020","unstructured":"Garcia-Morales, L. et al. A RAGE based strategy for the genome engineering of the human respiratory pathogen Mycoplasma pneumoniae. ACS Synth. Biol. 9, 2737\u20132748 (2020).","journal-title":"ACS Synth. Biol."},{"key":"1584_CR51","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1021\/acssynbio.0c00022","volume":"9","author":"C Pi\u00f1ero-Lambea","year":"2020","unstructured":"Pi\u00f1ero-Lambea, C. et al. Mycoplasma pneumoniae genome editing based on oligo recombineering and Cas9-mediated counterselection. ACS Synth. Biol. 9, 1693\u20131704 (2020).","journal-title":"ACS Synth. Biol."},{"key":"1584_CR52","doi-asserted-by":"publisher","unstructured":"Pi\u00f1ero-Lambea, C. et al. SURE editing: combining oligo-recombineering and programmable insertion\/deletion of selection markers to efficiently edit the Mycoplasma pneumoniae genome. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkac836 (2022).","DOI":"10.1093\/nar\/gkac836"},{"key":"1584_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-020-00153-7","volume":"6","author":"E Gaspari","year":"2020","unstructured":"Gaspari, E. et al. Model-driven design allows growth of Mycoplasma pneumoniae on serum-free media. NPJ Syst. Biol. Appl. 6, 33 (2020).","journal-title":"NPJ Syst. Biol. Appl."},{"key":"1584_CR54","doi-asserted-by":"publisher","first-page":"e1501632","DOI":"10.1126\/sciadv.1501632","volume":"2","author":"P Baker","year":"2016","unstructured":"Baker, P. et al. Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent Pseudomonas aeruginosa biofilms. Sci. Adv. 2, e1501632 (2016).","journal-title":"Sci. Adv."},{"key":"1584_CR55","doi-asserted-by":"publisher","first-page":"e00234-19","DOI":"10.1128\/AAC.00234-19","volume":"63","author":"MJ Pestrak","year":"2019","unstructured":"Pestrak, M. J. et al. Treatment with the Pseudomonas aeruginosa glycoside hydrolase PslG combats wound infection by improving antibiotic efficacy and host innate immune activity. Antimicrob. Agents Chemother. 63, e00234-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1584_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66293-2","volume":"10","author":"N Blanco-Cabra","year":"2020","unstructured":"Blanco-Cabra, N. et al. Characterization of different alginate lyases for dissolving Pseudomonas aeruginosa biofilms. Sci. Rep. 10, 9390 (2020).","journal-title":"Sci. Rep."},{"key":"1584_CR57","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/mbo3.210","volume":"3","author":"MGK Ghequire","year":"2014","unstructured":"Ghequire, M. G. K. et al. O serotype-independent susceptibility of Pseudomonas aeruginosa to lectin-like pyocins. MicrobiologyOpen 3, 875\u2013884 (2014).","journal-title":"MicrobiologyOpen"},{"key":"1584_CR58","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1099\/mic.0.070672-0","volume":"160","author":"A Elfarash","year":"2014","unstructured":"Elfarash, A. et al. Pore-forming pyocin S5 utilizes the FptA ferripyochelin receptor to kill Pseudomonas aeruginosa. Microbiology 160, 261\u2013269 (2014).","journal-title":"Microbiology"},{"key":"1584_CR59","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1073\/pnas.1420308112","volume":"112","author":"A Becker","year":"2015","unstructured":"Becker, A. et al. Structure of CARDS toxin, a unique ADP-ribosylating and vacuolating cytotoxin from Mycoplasma pneumoniae. Proc. Natl Acad. Sci. USA 112, 5165\u20135170 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1584_CR60","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1128\/JB.01228-10","volume":"193","author":"H-Y Chang","year":"2011","unstructured":"Chang, H.-Y., Jordan, J. L. & Krause, D. C. Domain analysis of protein P30 in Mycoplasma pneumoniae cytadherence and gliding motility. J. Bacteriol. 193, 1726\u20131733 (2011).","journal-title":"J. Bacteriol."},{"key":"1584_CR61","doi-asserted-by":"publisher","first-page":"e1002263","DOI":"10.1371\/journal.ppat.1002263","volume":"7","author":"SR Schmidl","year":"2011","unstructured":"Schmidl, S. R. et al. A trigger enzyme in Mycoplasma pneumoniae: impact of the glycerophosphodiesterase GlpQ on virulence and gene expression. PLoS Pathog. 7, e1002263 (2011).","journal-title":"PLoS Pathog."},{"key":"1584_CR62","doi-asserted-by":"publisher","first-page":"e10145","DOI":"10.15252\/msb.202010145","volume":"17","author":"V Garrido","year":"2021","unstructured":"Garrido, V. et al. Engineering a genome\u2010reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo. Mol. Syst. Biol. 17, e10145 (2021).","journal-title":"Mol. Syst. Biol."},{"key":"1584_CR63","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1165\/ajrcmb.24.5.4315","volume":"24","author":"RJ Martin","year":"2001","unstructured":"Martin, R. J., Chu, H. W., Honour, J. M. & Harbeck, R. J. Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. Am. J. Respir. Cell Mol. Biol. 24, 577\u2013582 (2001).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1584_CR64","doi-asserted-by":"publisher","first-page":"116625","DOI":"10.1016\/j.carbpol.2020.116625","volume":"246","author":"M Szyma\u0144ska","year":"2020","unstructured":"Szyma\u0144ska, M. et al. Glycoside hydrolase (PelAh) immobilization prevents Pseudomonas aeruginosa biofilm formation on cellulose-based wound dressing. Carbohydr. Polym. 246, 116625 (2020).","journal-title":"Carbohydr. Polym."},{"key":"1584_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fpubh.2020.00003","volume":"8","author":"B Magalh\u00e3es","year":"2020","unstructured":"Magalh\u00e3es, B. et al. Combining standard molecular typing and whole genome sequencing to investigate Pseudomonas aeruginosa epidemiology in intensive care units. Front. Public Health 8, 3 (2020).","journal-title":"Front. Public Health"},{"key":"1584_CR66","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1021\/acs.jproteome.0c00853","volume":"20","author":"R Olivella","year":"2021","unstructured":"Olivella, R. et al. QCloud2: an improved Cloud-based quality-control system for mass-spectrometry-based proteomics laboratories. J. Proteome Res. 20, 2010\u20132013 (2021).","journal-title":"J. Proteome Res."},{"key":"1584_CR67","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1002\/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2","volume":"20","author":"DN Perkins","year":"1999","unstructured":"Perkins, D. N., Pappin, D. J., Creasy, D. M. & Cottrell, J. S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551\u20133567 (1999).","journal-title":"Electrophoresis"},{"key":"1584_CR68","doi-asserted-by":"crossref","unstructured":"Beer, L. A., Liu, P., Ky, B., Barnhart, K. T. & Speicher, D. W. In Serum\/Plasma Proteomics Vol. 1619 (eds Greening, D. W. & Simpson, R. J.) 339\u2013352 (Springer, 2017).","DOI":"10.1007\/978-1-4939-7057-5_23"},{"key":"1584_CR69","doi-asserted-by":"publisher","first-page":"11033","DOI":"10.1093\/nar\/gkw880","volume":"44","author":"JA Vizca\u00edno","year":"2016","unstructured":"Vizca\u00edno, J. A. et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 44, 11033 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1584_CR70","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"1584_CR71","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1097\/CCM.0b013e31825332fc","volume":"40","author":"L Fern\u00e1ndez-Barat","year":"2012","unstructured":"Fern\u00e1ndez-Barat, L. et al. Linezolid limits burden of methicillin-resistant Staphylococcus aureus in biofilm of tracheal tubes: Crit. Care Med. 40, 2385\u20132389 (2012).","journal-title":"Care Med."},{"key":"1584_CR72","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"A-P Magiorakos","year":"2012","unstructured":"Magiorakos, A.-P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268\u2013281 (2012).","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01584-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T08:03:40Z","timestamp":1691741020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-022-01584-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1038\/s41587-022-01584-9","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"22 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The results published in this article are covered by patents US10745450B2, EP3262061A1 and PCT\/EP2021\/057122 (licensed to Pulmobiotics S.L) and PCT\/EP2021\/059142. L.S. and M.L. are shareholders of Pulmobiotics S.L.. R.M., C.P. and M.L. are employees and have stock options of Pulmobiotics S.L. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}